EXHIBIT 99.01 | |||
Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com | ![]() | ||
Press Release |
19 June 2007
Notification of major interests in shares
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:
Shire plc
2. Reason for the notification | State Yes/No |
An acquisition or disposal of voting rights | Yes |
An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | |
An event changing the breakdown of voting rights | |
Other (please specify): Revised due to DTR rules – see Section 13 | Yes |
3. Full name of person(s) subject to the notification obligation: | The Goldman Sachs Group Inc |
4. Full name of shareholder(s) (if different from 3.): | Goldman Sachs & Co |
5. Date of the transaction (and date on which the threshold is crossed or reached if different): | 14 June 2007 |
6. Date on which issuer notified: | 18 June 2007 |
7. Threshold(s) that is/are crossed or reached: | 3% |
8. Notified details: |
A: Voting rights attached to shares
Class/type of shares if possible using the ISIN CODE | Situation previous to the Triggering transaction | Resulting situation after the triggering transaction | |||||
Number of Shares | Number of Voting Rights | Number of shares | Number of voting rights | % of voting rights | |||
Direct | Direct | Indirect | Direct | Indirect | |||
US82481R1068 | Below 3% | 15,115,773 (5,038,591 ADRs) | 2.71% | ||||
GB00B0KQX869 | Below 3% | 1,708,016 | 0.31% |
Registered in England 5492592 Registered Office as above
B: Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument | Expiration date | Exercise/Conversion Period/ Date | Number of voting rights that may be acquired if the instrument is exercised/converted | % of voting rights |
Total (A+B) | |
Number of voting rights | % of voting rights |
16,823,789 | 3.02% |
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:
The interest in 1,708,016 shares arose from an interest held by Goldman, Sachs & Co., a wholly-owned direct subsidiary of GS Inc, acting as custodian for its customers. These shares are, or will be, registered in the name of Goldman Sachs Securities (Nominees), Limited. The interest in 15,070,260 shares arose from an interest held by Goldman, Sachs & Co., a wholly-owned direct subsidiary of GS Inc, acting as custodian for its customers of 5,023,420 American Depositary Receipts (“ADRs”). These ADRs are, or will be, held at the Depositary Trust Company of New York (“DTC”). The interest in 45,513 shares arose from an interest held by Goldman, Sachs & Co., a wholly-owned direct subsidiary of GS Inc, acting as discretionary manager for its customers of 15,171 American Depositary Receipts (“ADRs”). These ADRs are, or will be, held at the Depositary Trust Company of New York (“DTC”). |
Proxy Voting:
10. Name of the proxy holder: | N/A |
11. Number of voting rights proxy holder will cease to hold: | N/A |
12. Date on which proxy holder will cease to hold voting rights: | N/A |
13. Additional information: | General Email Contact: shareholderdisclosures@gs.com |
14. Contact name: | Joanne Wall/Sean Rogers |
15. Contact telephone number: | 44 (20)7051-1704/ 44(20)7552-9205 |
(Contact at Shire plc: Vivienne Hemming, Deputy Company Secretary, 01256 894276)
For further information please contact:
Investor Relations | Cléa Rosenfeld (Rest of the World) | +44 1256 894 160 |
Eric Rojas (North America) | +1 484 595 8252 |
Notes to editors
SHIRE PLC
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.
Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.
For further information on Shire, please visit the Company’s website: www.shire.com.